Drug news
Xtandi (enzalutamide) fails to meet its primary endpoint in Phase IV PLATO study to treat metastatic prostate cancer.-Pfizer + Astellas
Pfizer Inc. and Astellas Pharma Inc. announced the Phase IV PLATO study , evaluating the efficacy and safety of continued treatment with Xtandi (enzalutamide), plus abiraterone acetate and prednisone as compared to treatment with abiraterone acetate and prednisone alone, did not meet its primary endpoint of improvement in progression-free survival (PFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (CRPC) whose prostate-specific antigen (PSA) has previously progressed on Xtandi.